Q-Line Biotech Limited

l) Restatement of prior period expenses

During the restatement, Company has observed that many expenses of varied nature, like Expenses paid through Credit card, Audit Fees, Courier Charges, Manpower services, Repair and maintenance expenses, Consumable expenses, Factory Expenses, Travelling Expenses, Incentive expenses, royalty expenses, Service Charges (AMC) subcontractors, etc has been considered as expenses in audited Financial of FY 2024-25, therefore while doing restatement, expenses has been considered in respective year to which they pertains to and accordingly necessary effects has been given in Restated financials.

m) Restatement of Audited Consolidated Financial Statement of Respective year

During the restatement, Company has observed that Consolidated financial statement of the Company was prepared not in accordance with AS -21, AS â€“ 23 and accordingly necessary effect was taken in FY 2024-25 audited and accordingly necessary regrouping and adjustment were carried out in Audited Consolidated Financial Statement of the Company for the FY 2024-25 and previous year numbers were also restated and regrouped to align with the Compliance requirement of respective accounting standards.

For R K Jagetiya & Co
Chartered Accountants
FRN 146264W

FOR AND ON BEHALF OF THE BOARD
Q Line Biotech Limited

Saurabh Garg
MD & CHAIRMAN
DIN: 02891621

Amita Garg
WTD
DIN: 02891610

(CA Ravi K Jagetiya)
M. No. 134691
Proprietor
Date: 24th September, 2025
Place: Mumbai
UDIN:- 25134691BMGTLA9821

Akhand Pratap Singh
(CS)
Membership No.-

Place : Lucknow
Date: 24th September, 2025

Meenal Gupta
(CFO)
PAN -: